Acrivon Therapeutics, Inc.·4

Nov 16, 7:42 PM ET

Masson Kristina 4

4 · Acrivon Therapeutics, Inc. · Filed Nov 16, 2023

Insider Transaction Report

Form 4
Period: 2023-11-14
Masson Kristina
DirectorEVP - Business Operations
Transactions
  • Tax Payment

    Common Stock

    2023-11-14$5.08/sh1,900$9,652318,805 total
Holdings
  • Common Stock

    (indirect: See footnote)
    2,658,673
Footnotes (2)
  • [F1]Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
  • [F2]These securities are held by President and CEO, Peter Blume-Jensen, who is also Dr. Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

Documents

2 files